NCT01571596 - An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

June 30, 2014

Conditions

X-linked Hypophosphatemia

Interventions

DRUG

KRN23

Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.

Trial Locations (6)

27710

Duke Clinical Research Unit, Durham

46202

Clinical Research Center, Indiana University School of Medicine, Indianapolis

77030

University of Texas Health Science Center at Houston, Houston

94143

University of California San Francisco, San Francisco

06520

Yale University School of Medicine, New Haven

H3G 1A6

Shriners Hospital for Children - Canada, Montreal